Palisade Bio, Inc. Common Stock (PALI) is a publicly traded Healthcare sector company. As of May 21, 2026, PALI trades at $1.87 with a market cap of $314.54M and a P/E ratio of -6.08. PALI moved +4.42% today. Year to date, PALI is -10.48%; over the trailing twelve months it is +155.12%. Its 52-week range spans $0.53 to $4.32. Analyst consensus is strong buy with an average price target of $10.67. Rallies surfaces PALI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PALI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. PALI recently traded at $1.87. Market cap is $314.54M. P/E ratio is -6.08. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $1.87 |
| Market Cap | $314.54M |
| P/E Ratio | -6.08 |
| EPS | $-0.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.32 |
| 52-Week Low | $0.53 |
| Volume | 54 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-16.78M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-16.78M | $-0.30 |
| 2024 | $0 | $-14.44M | $-10.19 |
| 2023 | $250.00K | $-12.30M | $-1.80 |
| 2022 | $0 | $-14.26M | $-16.53 |
6 analysts cover PALI: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.67.